A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma

Piperno-Neumann, S., Carlino, M. S., Boni, V., Loirat, D., Speetjens, F. M., Park, J. J., Calvo, E., Carvajal, R. D., Nyakas, M., Gonzalez-Maffe, J., Zhu, X., Shirley, M. D., Ramkumar, T., Fessehatsion, A., Burks, H. E., Yerramilli-Rao, P., & Kapiteijn, E. (2023). A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma. British Journal of Cancer, 128(6), 1040–1051. https://doi.org/10.1038/s41416-022-02133-6

Authors:

S Piperno-Neumann

M S Carlino

V Boni

D Loirat

F M Speetjens

J J Park

E Calvo

R D Carvajal

M Nyakas

J Gonzalez-Maffe

X Zhu